Welcome to our dedicated page for Mynd Life Scienc news (Ticker: MYNDF), a resource for investors and traders seeking the latest updates and insights on Mynd Life Scienc stock.
MYND Life Sciences Inc. (MYNDF) is a clinical-stage biotechnology company advancing innovative diagnostic tools and therapies for depression treatment. This page serves as the definitive source for official news and press releases related to their biomarker development programs, neuropharmaceutical research, and corporate developments.
Investors and researchers will find timely updates on key initiatives including the MYND Anti-Inflammatory Peptide (MAP) diagnostic test, psilocybin-based therapeutic research, and strategic financial management activities. The curated news collection provides essential insights into clinical trial progress, intellectual property advancements, and partnership announcements.
All content undergoes rigorous verification to ensure accuracy and compliance with financial disclosure standards. Regular updates cover material developments across three core areas: diagnostic biomarker validation, drug candidate research, and balance sheet optimization strategies.
Bookmark this page for direct access to primary source information about MYNDF's progress in developing precision medicine solutions for neuropsychiatric disorders. Check back regularly for verified updates that matter to stakeholders in the life sciences investment community.
Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTC: RVLWF) has signed a binding letter of intent with MYND Diagnostics Inc. for a clinical research collaboration. This aims to study the relationship between diagnostic results using MYND's proprietary anti-inflammatory peptide biomarker (MAP) and improved patient outcomes in mental health. The initial clinical trials will focus on patients with post-COVID-19 mental health symptoms, utilizing Revitalist's network of over 2,300 patients. The goal is to submit MAP to the FDA for approval in Q2 2022, enhancing diagnostic accuracy and treatment efficacy.
MYND Life Sciences Inc. (CSE: MYND, OTC: MYNDF) announces a binding LOI with Revitalist Lifestyle and Wellness to collaborate on clinical research. This partnership aims to study the MAP biomarker’s effectiveness in diagnosing and monitoring mental health, particularly in patients experiencing post-COVID-19 symptoms like 'Brain Fog.' The objective is to provide a more objective diagnostic tool for healthcare providers and to gain FDA approval by Q2 2022. MYND anticipates generating revenue through research and aims to expand its mental health studies leveraging Revitalist's extensive clinic network.
MYND Life Sciences Inc. has announced significant changes to its Board of Directors. Aaron Bowden, a founding board member, has resigned, with the company expressing gratitude for his contributions. In his place, Scott L. Nicoll has been appointed as an independent director and interim Chair of the Audit Committee. Nicoll brings extensive legal and governance experience as a partner at Panorama Legal LLP and chair of Food Banks BC. The board is optimistic that his leadership will enhance the company's governance.
MYND Life Sciences (CSE: MYND, OTC: MYNDF) announced its agreement to acquire intellectual property rights from Cava Healthcare for the use of psychedelics in treating dementia, including Alzheimer's disease. The deal involves 450,000 common shares at a deemed price of $0.85 each and $120,000 in cash. MYND will also pay a yearly royalty of $240,000 or 4% of net sales. This acquisition aims to strengthen MYND's position in psychedelic treatments for neurodegenerative conditions.
MYND Diagnostics Inc. announced its participation in a proposed clinical trial to evaluate the efficacy of psilocybin-assisted psychotherapy for treatment-resistant depression (TRD). The trial aims to secure a portion of a $15 million fund from the Australian government and will employ MYND's proprietary biomarker technology. Led by Professor Paul Fitzgerald of Monash University, the phase 2b trial will assess the safety and efficacy of psilocybin treatments. If successful, it could lead to a multi-site phase 3 trial for regulatory approval within 12 months.
MYND Life Sciences Inc. (CSE:MYND)(OTC:MYNDF) will present at the VirtualInvestorConferences.com Psychedelics Conference on October 13, 2021, at 2:00 pm ET. CEO Dr. Lyle Oberg will lead the live, interactive event, allowing investors to ask questions in real-time. A recorded version will be available later for those who cannot attend. Recent company highlights include the launch of MYND Diagnostics Ltd., a $3 million convertible debenture offering, and a publication in The Lancet on Alzheimer's research. Interested investors can register here.
MYND Life Sciences has announced the formation of its diagnostic biomarker division through a wholly-owned subsidiary, MYND Diagnostics Ltd., aimed at enhancing diagnosis and treatment for patients with Major Depressive Disorder (MDD) and Treatment Resistant Depression (TRD). The subsidiary plans to generate revenue by Q2 2022 with the commercialization of the MYND Anti-inflammatory Peptide (MAP) biomarker. The global biomarkers market is forecast to grow from USD 41.47 billion in 2019 to USD 115.45 billion by 2027, enhancing MYND Diagnostics' potential in this expanding sector.
MYND Life Sciences Inc. has successfully closed a non-brokered private placement offering, achieving gross proceeds of $2.7 million from the sale of $3 million in convertible debenture units. Each unit comprises $1,000 principal unsecured convertible debentures and warrants to purchase common shares. The debentures bear 5% interest and mature in 24 months with a conversion price set at $0.75 per share. Proceeds will be utilized to advance its drug discovery platform and for general working capital.
MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) has announced a non-brokered private placement offering of debenture units totaling up to $3,000,000. Each debenture unit will consist of senior unsecured convertible debentures and common share purchase warrants. The debentures feature a 5% annual interest and can be converted into shares at $0.75 each. The funds will support the commercialization of its diagnostic division and advance ongoing clinical trials.
MYND Life Sciences Inc. (CSE: MYND, OTC: MYNDF) announced its eligibility for Depository Trust Company (DTC) services, facilitating easier trading of its stock for US investors. This development enhances MYND's access to US capital markets and could increase liquidity. CEO Dr. Lyle Oberg emphasized the potential for innovation in treating major depressive disorder, noting that 300 million individuals worldwide are underserved by current treatments. The DTC eligibility simplifies trading and settlement processes, positioning MYND for better investor engagement.
